News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
News FDA sets June date for Gilead's twice-yearly HIV PrEP Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.
News Gilead emerges victorious from HIV PrEP patent trial A US court has sided with Gilead Sciences in a dispute with the US government centred on the use of HIV medicines for pre-exposure prophylaxis.
News Gilead and US Government square up in court over PrEP Gilead Sciences will go to court this week to argue that it does not need to pay the US Government a share of the profits it has made on the use of its HIV drugs for pre-e
News Gilead gets big $175m judgment in HIV fraud case Massive judgment takes the total awarded to the pharma company to nearly $250 million.
News RFK Jr revives childhood vaccine task force HHS Secretary Kennedy adds yet another layer of scrutiny to childhood vaccines with the re-establishment of a task force disbanded in the 1990s.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face